ReviewFrontiers in endocrinology2020

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.

Erik J Tillman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.